C3N-02155
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 45.36071184
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650202 | — | — | 0.913 |
| 2 | SRR650141 | — | — | 0.913 |
| 3 | BS_09Z7TC35 | medulloblastoma | — | 0.896 |
| 4 | 085e4228-8ed7-44d7-9ab5-8a096434b650 | — | — | 0.896 |
| 5 | 5af838ac-ab79-41c0-81fb-168cf9b1cf50 | — | — | 0.894 |
| 6 | BS_45J79YTF | high-grade glioma | — | 0.892 |
| 7 | BS_W644VEVE | medulloblastoma | — | 0.892 |
| 8 | BS_3F5PR9GS | medulloblastoma | — | 0.891 |
| 9 | s0095110 | — | — | 0.891 |
| 10 | DRR168561 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |